Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

<< Previous

Bullboard Posts

Next >>

Post by Zachary07on Mar 08, 2021 12:23pm

162 Views

Post# 32743702

CBD Relieves Pain

Sponsored post CBD has been used to treat pain as far back as 2900 B.C. See related topics and articles about this by clicking it here!

It has been said that scientists have discovered that certain components of marijuana, including CBD, are responsible for its pain-relieving effects. The human body contains a specialized system called the endocannabinoid system (ECS), which is involved in regulating a variety of functions including sleep, appetite, pain and immune system response.

The body produces endocannabinoids, which are neurotransmitters that bind to cannabinoid receptors in your nervous system. Check the disclaimer on profile and landing page.

<< Previous

Bullboard Posts

Next >>

Golden Minerals closes Yoquivo gold-silver project sale